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In Brief
IL-36 cytokines require proteolytic
processing for activation, but how this is
achieved is unknown. Here, Henry et al.
show that proteases liberated from
activated neutrophils—cathepsin G,
elastase, and proteinase-3—differentially
process and activate all three IL-36 family
members. Therefore, neutrophil-derived
proteases can escalate inflammation
through processing of extracellular
cytokines.
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Recent evidence has strongly implicated the IL-1
family cytokines IL-36a, IL-36b, and IL-36g as key
initiators of skin inflammation. Similar to the other
members of the IL-1 family, IL-36 cytokines are
expressed as inactive precursors and require pro-
teolytic processing for activation; however, the
responsible proteases are unknown. Here, we show
that IL-36a, IL-36b, and IL-36g are activated differ-
entially by the neutrophil granule-derived proteases
cathepsin G, elastase, and proteinase-3, increasing
their biological activity 500-fold. Active IL-36 pro-
moted a strong pro-inflammatory signature in pri-
mary keratinocytes and was sufficient to perturb
skin differentiation in a reconstituted 3D human
skinmodel, producing features resembling psoriasis.
Furthermore, skin eluates from psoriasis patients
displayed significantly elevated cathepsin G-like
activity that was sufficient to activate IL-36b. These
data identify neutrophil granule proteases as potent
IL-36-activating enzymes, adding to our under-
standing of how neutrophils escalate inflammatory
reactions. Inhibition of neutrophil-derived proteases
may therefore have therapeutic benefits in psoriasis.INTRODUCTION
Interleukin 1 (IL-1) family cytokines, which include the recently
described IL-36a, b, and g proteins, play major roles as initiators
of inflammation and are frequently among the first cytokines pro-
duced in response to infection or injury (Kono and Rock, 2008;
Sims and Smith, 2010; Afonina et al., 2015). IL-1 family cytokines
are capable of triggering complex cascades of additional cyto-
kine production from diverse cell types, such as resident tissue
macrophages and dendritic cells as well as keratinocytes and
endothelial cells lining local blood vessels (Towne et al., 2004; Di-
narello, 2009; Vigne et al., 2011, 2012; Milovanovic et al., 2012).
IL-36a, IL-36b, and IL-36g are encoded by distinct genes, and
evidence is accumulating rapidly to suggest that these cytokines708 Cell Reports 14, 708–722, February 2, 2016 ª2016 The Authorsplay a key role in skin inflammation, particularly in psoriasis
(Blumberg et al., 2007, 2010; Johnston et al., 2011; Marrakchi
et al., 2011; Tortola et al., 2012; Towne and Sims, 2012; Farooq
et al., 2013; Kanazawa et al., 2013).
Individuals that carry hypomorphic mutations in the IL-36 re-
ceptor antagonist (IL-36RA) display a severe and highly debili-
tating form of psoriasis called generalized pustular psoriasis
(Marrakchi et al., 2011; Farooq et al., 2013; Kanazawa et al.,
2013). This suggests that deregulated IL-36 cytokine signaling
is sufficient to drive aggressive skin inflammation and also
that IL-36 is an important barrier cytokine. Analysis of IL-36
mRNA expression in skin biopsies from individuals with the
most common form of psoriasis, psoriasis vulgaris, found
dramatically elevated expression (100-fold) of all three IL-36
transcripts compared with non-lesional skin from the same indi-
viduals or non-affected controls (Blumberg et al., 2010; John-
ston et al., 2011). Consistent with the idea that elevated IL-36
activity is an initiating event in psoriasis, transgenic expression
of IL-36a in the mouse leads to a psoriasis-like condition at birth
that can be exacerbated further with the skin irritant phorbol
acetate (Blumberg et al., 2007). Moreover, application of a Toll
receptor agonist (imiquimod) to the skin of humans and mice
can provoke psoriasis outbreaks (Wu et al., 2004; Tortola
et al., 2012) that are increased in severity in IL-36RA/ mice
(Tortola et al., 2012). Furthermore, imiquimod-induced psoriasis
in mouse models is abolished completely on an IL-36R/ back-
ground (Tortola et al., 2012). Finally, transplantation of human
psoriatic lesions onto immunodeficient (severe combined im-
munodeficiency) mice produces a psoriasis-like condition that
is greatly improved through blocking the IL-36 receptor (Blum-
berg et al., 2010).
IL-36a, IL-36b, and IL-36g are all generated as leaderless cy-
tokines that lack biological activity (Towne et al., 2011). There-
fore, proteolytic processing of IL-36 cytokines is required to
unleash their pro-inflammatory activity, similar to other members
of the IL-1 family, such as IL-1b and IL-18 (Afonina et al., 2015).
Sims and colleagues (Towne et al., 2011) have shown that
removal of a small number of residues from the N termini of
IL-36a, IL-36b, and IL-36g increases their biological activity by
more than 10,000-fold. Because IL-36 cytokines appear to
play a key role as initiators of inflammation in the skin barrier,
inhibitors of IL-36 proteolytic activation may have consider-
able potential for the treatment of inflammatory skin conditions.
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Figure 1. IL-36 Cytokines Require Processing to Release Biological Activity
(A) Schematic of modified forms of IL-36a, IL-36b, and IL-36gwhere a caspase-3-processingmotif (DEVD) was inserted into the IL-36 sequence N-terminal to the
known artificial processing sites (Towne et al., 2011).
(B) Recombinant IL-36a/b/g and DEVD-IL-36a/b/gwere incubated at 37C for 2 hr either alone or in the presence of the indicated concentrations of recombinant
caspase-3, followed by immunoblot analysis. MW, molecular weight.
(C) HeLaVector and HeLaIL-36R cells were either left untreated (UT) or stimulated with caspase-3-cleaved DEVD-IL-36a, b, or g. After 24 hr, cytokine concentrations
in the culture supernatants were determined by ELISA.
(D) HeLaIL-36R cells were stimulatedwith either full-length IL-36a/b/g or caspase-3-cleavedDEVD-IL-36a/b/g at the indicated concentrations. After 24 hr, cytokine
concentrations in the culture supernatants were determined by ELISA. Diagonal lines indicate a break on the y axis.
The results shown are representative of at least three independent experiments. Error bars represent the mean ± SEM of triplicate determinations from a
representative experiment. See also Figure S1.However, the proteases responsible for activation of IL-36 cyto-
kines are currently unknown.
Here we show that the neutrophil-derived proteases cathepsin
G, elastase, and proteinase-3 are potent IL-36-activating en-
zymes. Because psoriasis plaques are frequently associated
with neutrophil infiltrates (Terui et al., 2000; Murphy et al.,
2007; Ikeda et al., 2013), this suggests that inhibitors of
neutrophil granule proteases may have significant potential as
inhibitors of IL-36-dependent inflammation in psoriasis. Further-
more, these observations also suggest that neutrophils amplify
inflammation through liberation of granule proteases into the
extracellular space that can process and activate multiple IL-1
family cytokines.
RESULTS
Truncated IL-36 Proteins Exhibit Biological Activity
To identify the proteases responsible for processing and activa-
tion of IL-36 cytokines, we established an IL-36 bioassay byCstably transfecting HeLa cells with the human IL-36 receptor
(IL-36R). Sims and colleagues (Towne et al., 2011) have reported
that artificial truncation of IL-36a, b, and g at particular N-termi-
nal residues dramatically increases the activity of these proteins
(Figure 1A). To confirm that HeLaIL-36R cells were IL-36-respon-
sive, we created modified forms of IL-36a, b, and g by inserting a
caspase-3 cleavage motif, DEVD, proximal to the residues
identified by Sims and colleagues (Towne et al., 2011) that are
capable of generating biologically active IL-36 cytokines (Fig-
ure 1A). DEVD-modified IL-36a, b, and gwere processed readily
by caspase-3 whereas their wild-type counterparts were not
(Figure 1B). HeLavector cells failed to respond to either full-length
or caspase-3-cleaved IL-36 cytokines, whereas HeLaIL-36R
cells secreted multiple cytokines in response to caspase-3-pro-
cessed, DEVD-modified forms of IL-36a, b, and g but not
full-length, unprocessed forms of these cytokines (Figures 1C
and 1D). Furthermore, the spontaneously immortalized keratino-
cyte line HaCat, which naturally expresses the IL-36R, also re-
sponded to the caspase-3-cleaved IL-36DEVD forms. (Figure S1).ell Reports 14, 708–722, February 2, 2016 ª2016 The Authors 709
These data confirmed that proteolytic processing of IL-36a, b,
and g dramatically increases the biological activity of these cyto-
kines and validated HeLaIL-36R cells as a bioassay to screen for
proteases that naturally activate IL-36 cytokines.
Neutrophil-Derived Proteases Activate IL-36 Cytokines
One of the hallmarks of psoriatic lesions is persistent infiltration
of the epidermis by neutrophils (Terui et al., 2000; Murphy
et al., 2007; Ikeda et al., 2013). Neutrophil secretory granules
contain three major serine proteases (elastase, cathepsin G,
and proteinase-3) that are involved in bacterial killing as well as
in the processing of certain cytokines and chemokines (Korkmaz
et al., 2010). To explore whether neutrophil-derived proteases
can process and activate IL-36 cytokines, we induced human
peripheral blood neutrophils to degranulate with phorbol-12-
myristate 13-acetate (PMA) (Brinkmann et al., 2004), thereby
liberating granule proteases and generating reactive oxygen
species (ROSs) (Figures 2A and 2B). Robust ROS production
and protease activity was found in supernatants from PMA-
treated neutrophils, as expected (Figure 2B). Purified full-length,
wild-type IL-36a, b, and g were then incubated with superna-
tants from untreated versus PMA-activated neutrophils, followed
by assessment of IL-36 activity using HeLaIL-36R cells. As shown
in Figure 2C, incubation of IL-36 cytokines in the presence of
PMA-activated neutrophil supernatants resulted in robust acti-
vation of IL-36b and IL36g, whereas IL-36a was activated
more modestly under the same conditions.
Identification of IL-36-Activating Proteases
To identify the specific protease(s) involved in IL-36a, b, and
g activation, we initially used a panel of broad-spectrum prote-
ase inhibitors. As Figure 2D illustrates, the serine protease inhib-
itor PMSF potently inhibited activation of IL-36a, b, and g by
activated (i.e., PMA-treated) neutrophil supernatants. A specific
chemical inhibitor of cathepsin G (CatG inhibitor I) robustly in-
hibited the activation of IL-36b, whereas a chemical inhibitor of
elastase activity (elastase inhibitor IV), which inhibits both elas-
tase and proteinase-3, inhibited the activation of IL-36g by acti-
vated neutrophil supernatants (Figure 2D; Figures S2A–S2C).
Interestingly, IL-36a activation by neutrophil degranulates was
inhibited by both elastase and cathepsin G inhibitors, suggesting
that both of these enzymes contribute to the activation of this
cytokine (Figure 2D). To further explore the identity of the IL-36
processing protease(s), we used a panel of protease inhibitors
specific for either cathepsin G or elastase. As Figure 2E demon-
strates, two different cathepsin G-specific inhibitors (CatG inhib-
itor I and FLF-chloromethylketone [FLF-cmk]) potently inhibited
IL-36b activation by neutrophil supernatants but did not inhibit
IL-36g activation under the same conditions. In contrast, neutro-
phil supernatant-mediated IL-36g activation was antagonized
by an inhibitor of elastase-like activity (elastase inhibitor IV),
whereas cathepsin G inhibitors did not antagonize activation of
the latter (Figure 2E; Figures S2A–S2C). We also generated a
biotin-conjugated form of the cathepsin G inhibitor, biotin-FLF-
CMK, to ask whether this depleted the IL-36b-activating activity
from neutrophil supernatants. As Figure 2F illustrates, biotin-
FLF-CMK selectively depleted cathepsin G activity (FLF-thio-
benzyl ester [FLF-sBzl] hydrolysis) from PMA-treated neutrophil710 Cell Reports 14, 708–722, February 2, 2016 ª2016 The Authorssupernatants but did not deplete elastase activity (AAPV-7-
amino4-methyl-courmarin [AAPV-AMC] hydrolysis). Further-
more, FLF-CMK specifically inhibited purified cathepsin G but
not purified elastase (Figure 2F, right). Consistent with this,
biotin-FLF-CMK-depleted neutrophil supernatants failed to
activate IL-36b but remained competent to activate IL-36g (Fig-
ure 2G). Collectively, these data strongly suggest that cathepsin
G processes and activates IL-36b and that an elastase-like activ-
ity (which could be either elastase itself or proteinase-3, which
has a similar specificity to the latter protease) activates IL-36g.
Purified Cathepsin G, Elastase, and Proteinase-3
Activate IL-36 Cytokines
We next compared the ability of purified cathepsin G, elastase,
and proteinase-3 to process and activate IL-36 cytokines. The
activity of all purified proteases was confirmed using synthetic
substrate peptides (Figure 3A). As Figure 3B and Figure S3B
demonstrate, and in agreement with our previous observations
using primary human neutrophil supernatants, purified cathepsin
G selectively promoted IL-36b activation, whereas both elastase
and proteinase-3 preferentially activated IL-36g. IL-36a was
activated by incubation with either cathepsin G or elastase under
the same conditions (Figure 3B). Because caspase-1 processes
and activates the IL-1 family cytokines IL-1b and IL-18 we also
explored whether caspase-1 or caspase-3 could process and
activate IL-36 family cytokines. However, as Figure 3B illus-
trates, neither caspase activated any of the IL-36 cytokines. To
confirm the above observations, we also titrated IL-36 cytokines
over a wide concentration range in the presence and absence of
a fixed concentration (100 nM) of cathepsin G, elastase, or pro-
teinase-3. As Figure 3C shows, IL-36a was again activated by
cathepsin G or elastase and, to a lesser extent, by proteinase-
3, with IL-36b activated preferentially by cathepsin G, whereas
IL-36g was activated by either elastase or proteinase-3 (Fig-
ure 3C). Furthermore, we also confirmed processing of IL-36
cytokines by purified neutrophil proteases or activated neutro-
phil degranulates by immunoblot analysis (Figures S3A and
S3B). However, as Figures S3A and S3B demonstrate, although
certain IL-1 family members (IL-1b and IL-18) were also pro-
cessed by neutrophil proteases, these processing events failed
to generate biologically active cytokines. In contrast, IL-1a was
both processed and activated by all three neutrophil-derived
proteases, as reported previously (Afonina et al., 2011). There-
fore, multiple (but not all) members of the extended IL-1 family
are activated through processing by proteases liberated by acti-
vated neutrophils.
Elastase Is the Major IL-36g-Processing Enzyme in
Neutrophil Degranulates
Because both elastase and proteinase-3 were capable of
robustly processing and activating IL-36g (Figures 3B and 3C),
we next sought to determine which of these proteases contrib-
utes the majority of the IL-36g-processing activity in neutrophil
degranulates. To address this issue, we immunodepleted elas-
tase or proteinase-3 from activated neutrophil degranulates
using specific antibodies. Immunodepletion of elastase led to
a very significant reduction in AAPV-AMC hydrolysis (Figure 3D,
top), whereas depletion of proteinase-3 had a much more
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modest effect in the same assay. Consistent with this, depletion
of elastase robustly attenuated the activation of IL-36g by
neutrophil degranulates, suggesting that proteinase-3 plays a
minor role in this context (Figure 3D, bottom). As expected
from our earlier results, depletion of elastase or proteinase-3
did not affect processing of IL-36b, whereas inhibition of
cathepsin G activity with a specific CatG inhibitor (CatG i)
completely attenuated activation of IL-36b by neutrophil degra-
nulates or purified cathepsin G (Figure 2E, left; Figure S3C).
Taken together, these data argue that, although proteinase-3
can (in principle) process and activate IL-36b and IL-36g when
present at sufficient concentrations, at the concentrations found
in neutrophil degranulates, elastase is the major IL-36g-acti-
vating enzyme, and cathepsin G is the primary instigator of
IL-36b activation.
Cell-Associated IL-36 Cytokines Are Cleaved and
Activated by Neutrophil Proteases
To explore whether cell-derived, as opposed to recombinant,
IL-36 cytokines were activated by neutrophil proteases, we
expressed the full-length forms of these cytokines in HEK293T
cells (Figure 4A). IL-36 cytokines were expressed as full-length
proteins without any discernable cleavage products (Figure 4A).
However, upon incubation of lysates from these cells with either
cathepsin G (Figure 4B) or elastase (Figures 4C and 4D), proteol-
ysis of IL-36 cytokines was detected. Furthermore, proteolysis of
cell-derived IL-36b by cathepsin G, but not by elastase, resulted
in robust biological activity (Figures 4E and 4H). Conversely,
proteolysis of cell-derived IL-36g by elastase, but not cathepsin
G, potently activated this cytokine (Figures 4F and 4I). In accor-
dance with previous results, proteolysis of cell-derived IL-36a by
either cathepsin G or elastase resulted in activation of the latter
(Figure 4G). Collectively, these data demonstrate that neutro-
phil-derived proteases are potent instigators of IL-36-activation.
Mapping of Cathepsin G and Elastase Cleavage Sites
within IL-36 Cytokines
To identify the cathepsin G cleavage site(s) within IL-36b that
result in activation, we performed N-terminal Edman degrada-
tion sequencing of cathepsin G-treated IL-36b preparations.Figure 2. Degranulates from Activated Neutrophils Can Promote IL-36
(A) Primary human neutrophils were stimulated with PMA (50 nM) for 3 hr. Cells w
(B) Primary human neutrophils stimulated with PMA as in (A). ROS-positive cells w
by flow cytometry, and cathepsin G (CatG) enzymatic activity was measured by
(C) HeLaIL-36R cells were stimulated with IL-36a, b, or g (500 pM) pre-incubated f
degranulates. After 24 hr, cytokine concentrations in the culture supernatants (s/
(D) HeLaIL-36R cells were stimulated with IL-36a (1 nM), IL-36b (500 pM), or IL-36
presence or absence of PMSF (1 mM), leupeptin (Leu, 10 mg/ml), aprotinin (Apro,
zVAD-fmk (zVAD, 10 mM), N-[N-(N-acetyl-L-leucyl)-L-leucyl]-L-norleucine (ALLN,
supernatants were determined by ELISA.
(E) HeLaIL-36R cells were stimulatedwith IL-36b or IL-36g (500 pM) pre-incubated fo
(10 mM), Elast i (10 mM), and biotin-FLF-CMK (5 mM). After 24 hr, cytokine conce
(F) Control and PMA-activated neutrophil degranulates were pre-incubated with
with streptavidin-agarose beads. Degranulates were subsequently assessed for
relative fluorescence unit.
(G) HeLaIL-36R cells were stimulated with IL-36b or IL-36b (500 pM) pre-incu
degranulates. After 24 hr, cytokine concentrations in the culture supernatants we
Error bars represent the mean ± SEM of triplicate determinations from a repre
independent experiments. ***p < 0.0001; **p < 0.001; *p < 0.1; ns, not significant
712 Cell Reports 14, 708–722, February 2, 2016 ª2016 The AuthorsThis analysis identified two candidate sites at Arg5 and Phe53
(Figure 5A). Therefore, we generated point mutations (R5A,
F53A) at both of these sites to assess their role in cathepsin
G-mediated activation of IL-36b. We initially tested each mutant
for resistance to proteolysis by cathepsin G. As Figure 5B shows,
mutation at Phe53 in IL-36b suppressed the appearance of the
two major cleavage bands (10 and4 kDa) but retained a third
cleavage product (17 kDa) just below the full-length protein. In
contrast, mutation at Arg5 eliminated the faint17-kDa cleavage
product but only partly affected the major cleavage products at
10 and4 kDa (Figure 5B). However, as Figure 5C and Figures
S4A–S4C illustrate, although mutation of Phe53 had no effect
on cathepsin G-mediated IL-36b activation, mutation of Arg5
dramatically abolished activation of this cytokine. The R5A
mutant also completely abolished proteinase-3-mediated
IL-36b activation (Figure S4D). Furthermore, mutation of Arg5
also abolished activation of IL-36b by PMA-activated neutrophil
supernatants (Figure 5D). Using a similar approach, we identified
Val15 in IL-36g as the residue that is cleaved by elastase to
promote activation of the latter (Figures 5E–5G). Mutation of
this residue (V15G) also dramatically attenuated activation of
IL-36g by elastase and proteinase-3 aswell as by PMA-activated
neutrophil degranulates (Figure 5H; Figure S4E). Finally, we iden-
tified Lys3 and Ala4 in IL-36a as the residues cleaved by cathe-
spin G and elastase, respectively (Figure 5I). The identities of the
sites within IL-36 cytokines that are processed by all three
neutrophil-derived proteases to activate the latter are summa-
rized in Figure 5J.
Active IL-36b Induces the Expression of Numerous
Pro-inflammatory Genes in Primary Keratinocytes
To further explore the biological effects of active IL-36, we con-
ducted a gene expression array analysis of cathepsin G-pro-
cessed IL-36b in primary human keratinocytes. As Figure 6A
demonstrates, active IL-36b induced robust expression of a
diverse array of pro-inflammatory cytokines and chemokines
from keratinocytes. Of particular note, IL-36 induced strong
transcriptional upregulation of IL-17C (50-fold within 8 hr), a
cytokine that has been implicated as a key driver of the pathol-
ogy observed in psoriasis and other inflammatory conditionsProcessing and Activation
ere visualized by phase contrast microscopy.
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Figure 3. Neutrophil-Derived Proteases Activate IL-36 Cytokines
(A) Hydrolysis of synthetic substrates (Ac-WEHD-AMC, Ac-DEVD-AMC, suc-FLF-sBzl, and Suc(oMe)-AAPV-AMC) by recombinant caspase-1 (1:20), caspase-3
(400 nM), cathepsin G (20 nM), elastase (50 nM), and proteinase 3 (100 nM).
(B) HeLaIL-36R cells were stimulated with IL-36a, b, or g (500 pM) pre-incubated for 2 hr at 37C with the indicated concentrations of recombinant caspase-1,
caspase-3, or purified cathepsin G, elastase, or proteinase-3. IL-1b p17 (25 nM) served as a positive control for caspase titrations. After 24 hr, cytokine
concentrations in the culture supernatants were determined by ELISA.
(C) HeLaIL-36R cells were stimulated with a titration of IL-36a, b, and g pre-incubated for 2 hr at 37C with fixed concentrations of purified cathepsin G (50 nM),
elastase (100 nM), or proteinase-3 (100 nM). After 24 hr, cytokine concentrations in the culture supernatants were determined by ELISA.
(legend continued on next page)
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(Ramirez-Carrozzi et al., 2011). IL-36b also induced strong
expression of multiple additional inflammatory factors, such as
complement C3, b-defensin-2, S100A9, tumor necrosis factor
a (TNF-a), and granulocyte colony-stimulating factor (G-CSF),
which are frequently elevated in lesional skin from psoriatic
patients (Figure 6A; Ramirez-Carrozzi et al., 2011; Schonthaler
et al., 2013). Interestingly, we also found that IL-36b induced a
strong signature of IL-36g upregulation in primary keratinocytes,
suggesting that this cytokine can promote a positive feedback
loop for further IL-36 expression (Figure 6A). Using primary
human keratinocytes, we confirmed that cathepsin G-activated
IL-36 induced robust expression of IL-17C, G-CSF, granulo-
cyte-macrophage CSF (GM-CSF), and other inflammatory fac-
tors at the mRNA (Figure 6B) and protein levels (Figures 6C
and 6D; Figure S5A), whereas full-length IL-36 had little activity
under the same conditions. Similar results were found using
the spontaneously immortalized keratinocyte line HaCat (Fig-
ure S5B). As illustrated in Figure S5B, full-length IL-36b or
IL-36g exhibited little activity on HaCat cells, whereas cathepsin
G-activated IL-36b and elastase-activated IL-36g induced
robust production of cytokines in these cells.
Active IL-36 Perturbs Differentiation in a 3D
Organotypic Skin Model
To explore the biological effects of active IL-36 in a more phys-
iologically relevant setting, we utilized a well established model
of reconstituted human skin with primary keratinocytes and
dermal fibroblasts (Vo¨rsmann et al., 2013). Remarkably, we
found that, although full-length (inactive) IL-36 had little effect
in this model, cathepsin G-processed IL-36b was sufficient to
perturb skin differentiation with significant epidermal thickening
and expanded stratum layers, similar to the hyperproliferative
pathology of psoriasis (Figures 7A and 7B). These data suggest
that active IL-36 cytokines may directly contribute to the patho-
logical features of psoriasis through initiating not only the
expression of a diverse array of pro-inflammatory cytokines
and chemokines but also through stimulating the production of
keratinocyte growth factors. In this context, it is highly relevant
to note that previous studies have shown that the related cyto-
kine IL-1a has been found to trigger production of keratinocyte
growth factor (KGF) and epidermal growth factor (EGF) from fi-
broblasts (Maas-Szabowski et al., 2000). Although exploring
this was outside of the scope of this study, it is highly plausible
that IL-36 cytokines also exert at least some of their effects via
fibroblasts as well as through effects on keratinocytes.
Psoriatic Human Skin Exhibits Elevated Cathepsin
G-like Activity that Is Sufficient to Activate IL-36b
Neutrophil infiltration is a pathological hallmark of awide range of
inflammatory conditions, including inflammatory skin conditions
such as psoriasis (Terui et al., 2000; Murphy et al., 2007; Amulic
et al., 2012; Ikeda et al., 2013). Therefore, we sought to deter-(D) Top: elastase activity was measured with AAPV-AMC peptide from activate
agarose alone), anti-IgG, anti-elastase, or anti-proteinase-3 antibodies (1.5 mg) f
IL-36g (500 pM) pre-incubated for 2 hr at 37C with activated neutrophil degranul
anti-elastase, or anti-proteinase-3 antibodies (1.5 mg) for 3 hr at 4C. After 24 hr, c
All data shown are representative of at least three independent experiments. ***p
714 Cell Reports 14, 708–722, February 2, 2016 ª2016 The Authorsminewhether skin frompatients with a common formof psoriasis
(psoriasis vulgaris) exhibited elevated neutrophil protease activ-
ity. To explore this, we collected tape-stripped skin samples
from healthy or psoriatic human volunteers, followed by elution
of proteins from these samples and measurement of AAPV-
AMC (elastase-like) versus FLF-sBzl (cathepsin G-like) hydroly-
sis activity. Significantly, although none of the samples displayed
elevated elastase/proteinase-3 (i.e., AAPVase) activity, skin elu-
ates from psoriatic individuals displayed dramatically elevated
levels of cathepsin G activity (Figure 7C). Next we tested the
ability of these skin eluates to activate exogenously added
IL-36 cytokines. Consistent with the synthetic peptide hydrolysis
results, IL-36b was activated robustly and selectively by eluates
from psoriatic individuals (Figure 7D). In line with the absence of
elevated elastase or proteinase-3 activity in any of the skin elu-
ates, IL-36a and IL-36g failed to be activated under the same
conditions. Furthermore, a specific inhibitor of cathepsin G
(CatG i) completely suppressed activation of IL-36b in eluates
from psoriatic individuals, whereas inhibition of elastase had
no effect (Figure 7D, right). These data provide preliminary evi-
dence that cathepsin G levels are elevated in psoriatic skin and
that this enzyme is responsible for the processing and activation
of IL-36b in this context.
DISCUSSION
Here we report that IL-36 family cytokines are activated by
neutrophil-derived granule proteases (Figure 5J). Biologically
active IL-36 was found to induce a panoply of pro-inflammatory
factors from primary human keratinocytes, many of which are
known to be upregulated in lesional skin from psoriasis patients
(Johnston et al., 2011; Ramirez-Carrozzi et al., 2011;
Schonthaler et al., 2013). Active IL-36 was also sufficient to
perturb differentiation in a human reconstituted 3D skin model,
suggesting that one or more IL-36-induced factors may be
directly responsible for the hyperproliferation and impaired
differentiation observed in psoriatic skin. Consistent with our ob-
servations that cathepsin G can process and activate IL-36b,
we have also found that cathepsin G activity is elevated dramat-
ically in human psoriatic skin elutes and that this activity was
capable of activating IL-36b.
SequenceMapping of Neutrophil Cleavage Sites in IL-36
Cytokines
Although it is known, through deletion analysis, that IL-36 cyto-
kines require processing at their N termini for activation (Towne
et al., 2011), the proteases that naturally process and activate
these cytokines have not been identified until now. We identified
Arg5 as the critical residue required for IL-36b activation by
cathepsin G. We also identified another cathepsin G cleavage
site within IL-36b, Phe53, but found, through mutagenesis, that
processing at this site was not required for activation. However,d neutrophil degranulate that had been pre-depleted with either mock (A/G
or 3 hr at 4C. Bottom: HeLaIL-36R cells were stimulated with IL-36a, IL-36b or
ate that had been pre-depleted with either mock (A/G agarose alone), anti-IgG,
ytokine concentrations in the culture supernatants were determined by ELISA.
< 0.0001, **p < 0.001, *p < 0.1, Student’s t test. See also Figure S3.
A B
Actin
IL-36β
IL-36γ
)a
Dk(
w
M 17
UT GF
P-
IL-
36
β
IL-
36
γ
46
FL
AG
-IL
-36
γ
17
30
239T
C
UT 10
0 50
IL-36β
17
)a
Dk(
w
M
30
GFP-IL-36β
IL-
36
β
IL-
36
β
Ca
t-G
7
_
Cat G (nM)
Cat G 
(nM)
Elastase
(nM)
l
m/gn
0
2.0
IL-6
3.0
4.0
0
GFP-IL-36β
1.0
1.0
0.5
1.5
l
m/gn
IL-8
5010
0 255010
0 25
IL-6
GFP-IL-36β
0
14
12
16
10
8
6
l
m/gn
0
6.0
5.0
7.0
l
m/gn
IL-8
IL-36 (293T S/N)
UT 1:2
0
1:4
0
1:8
0
1:1
60
4.0
3.0
0.2
IL-36 (293T S/N)
UT 1:2
0
1:4
0
1:8
0
1:1
60
l
m/gn
IL-36γ
l
m/gn
IL-8
0
0.4
0.3
0.5
0.2
0.1
0.6
0
0.4
0.6
0.8
0.2
0.7
0.5
0.1
0.3
UT 10
0
50 25
Elastase (nM)
IL-36γ
17
)a
Dk(
w
M 7
IL-
36
γ
IL-
36
γE
las
t
IL-36γ
_
IL-6
IL-36γ
IL-36 (293T S/N)
UT 1:4
0
1:8
0
1:1
00
0
2.0
1.5
1.0
0.5
0
1.0
l
m/gn
IL-8
0.8l
m/gn
IL-36 (293T S/N)
UT 1:4
0
1:8
0
1:1
00
0.6
0.4
0.2
10
0
0.1
4
2
Untreated
Cathepsin G
Elastase
UT
IL-
36
β
Cat G 
(nM)
Elastase
(nM)
5010
0 255010
0 25UT
IL-
36
β
Cat G 
(nM)
Elastase
(nM)
5010
0 255010
0 25UT
IL-
36
γ
Cat G 
(nM)
Elastase
(nM)
5010
0 255010
0 25UT
IL-
36
γ
UT 10
0 50 25
Elastase (nM)
IL-36γ
17
)a
Dk(
w
M
FLAG-IL-36γ
7
IL-
36
γ
IL-
36
γE
las
t
_
IL-6
IL-36α
IL-36 (293T S/N)
UT 1:4
0
1:8
0
1:1
00
0
3.5
3.0
2.5
2.0
0
1.0
l
m/gn
IL-8
0.8
Untreated
Cathepsin G
Elastase
l
m/gn
IL-36 (293T S/N)
UT 1:4
0
1:8
0
1:1
00
0.6
0.4
0.2
1.5
1.0
0.5
1.2
D
E F
G H
I
Figure 4. Cell-Associated IL-36 Cytokines Are Processed and Activated by Neutrophil-Derived Proteases
(A) HEK293T cells were transfected with plasmids encoding GFP-IL-36b (2 mg), FLAG-IL-36g (2 mg), or IL-36g (2 mg) and incubated for 48 hr. Cells were sub-
sequently lysed using streptolysin O (SLO) (5 mg/ml). Whole-cell lysates were analyzed by immunoblot.
(B–D) Cell lysate preparations from cells overexpressing GFP-IL-36b, IL-36g, or FLAG-IL-36gwere incubated with the indicated concentration of cathepsin G (B)
or elastase (C and D), followed by immunoblot analysis. Recombinant IL-36b/g incubated with purified cathepsin G and elastase served as controls.
(E and F) HeLaIL-36R cells were either left untreated or stimulatedwith HEK293T lysate containing GFP-IL-36b (E) or IL-36g (F), whichwere pre-incubated for 2 hr at
37C with the indicated concentrations of cathepsin G or elastase. After 24 hr, cytokine concentrations in the culture supernatants were determined by ELISA.
(G–I) HeLaIL-36R cells were either left untreated or stimulated with the indicated dilutions of HEK293T lysate containing IL-36a (G), GFP-IL36b (H), or IL-36g (I),
which were pre-incubated for 2 hr at 37C with cathepsin G (50 nM) or elastase (50 nM), as indicated. After 24 hr, cytokine concentrations in the culture
supernatants were determined by ELISA.
Error bars represent the mean ± SEM of triplicate determinations from a representative experiment. All data shown are representative of at least three inde-
pendent experiments.replacement of Arg5 with an alanine (R5A) completely abolished
the ability of cathepsin-G and proteinase-3 to activate IL-36b
(Figure 5; Figure S4). Although Sims and colleagues (TowneCet al., 2011) have shown that truncation of IL-36b after Gln4
greatly enhances biological activity, no protease has been
identified that cleaves IL-36b at this site. We also mapped theell Reports 14, 708–722, February 2, 2016 ª2016 The Authors 715
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elastase and proteinase-3 cleavage sites within IL-36g and iden-
tified Val15 as the critical residue required for processing of the
latter by either protease. In contrast, Sims and colleagues
(Towne et al., 2011) have reported previously that truncation
of IL-36g after Gln17 greatly enhanced biological activity. How-
ever, a protease capable of cleaving IL-36g at Gln17 remains
unknown.
Neutrophils and Psoriatic Inflammation
Immune cell infiltration is a hallmark of a number of skin-related
inflammatory diseases. In particular, psoriatic plaques are heavi-
ly infiltrated with neutrophils, dendritic cells, macrophages, and
T cells (Terui et al., 2000; Murphy et al., 2007; Nestle et al.,
2009). Neutrophils are first responder cells in the innate immune
system and play a critical role in the initial response to infection
or tissue damage (Pham, 2006; Borregaard et al., 2007; Kolacz-
kowska and Kubes, 2013). Although release of neutrophil prote-
ases can exert profound antimicrobial and protective effects
during infection, these proteases can also provoke extensive tis-
sue damage and exacerbate inflammation (Garver et al., 1986;
Hubbard et al., 1991; Wiedow et al., 1992). Interestingly, the
onset of psoriasis symptoms in affected individuals often follows
a streptococcus A or viral infection (Telfer et al., 1992), which is
associated with robust neutrophil andmacrophage infiltration as
well as necrosis of infected tissue. Psoriatic lesions can also
develop as a result of physical injuries such as lacerations, burns,
or surgical incisions (Weiss et al., 2002). Therefore, a feature that
unites the above scenarios is that all are capable of triggering
necrotic cell death in the epidermis, which results in neutrophil
infiltration (Kono and Rock, 2008). As a consequence of necro-
sis, endogenous alarmins such as IL-36 and other IL-1 family
cytokines are released into the extracellular space where they
may become processed by proteases liberated from activated
neutrophils. Therefore, damage to keratinocytes resulting in
the liberation of IL-36 cytokines, either as a result of microbial
infection or through tissue trauma, may play an important initi-Figure 5. Mapping the Cleavage Sites of Neutrophil-Derived Proteases
(A) Recombinant IL-36b (2 mg) was incubated with cathepsin G (50 nM) for 2 h
degradation sequencing. Also shown is a schematic representing the NPQR5 an
pendent experiments.
(B) Recombinant IL-36b, IL-36bF53A, and IL-36bR5A (2 mg) were incubated with a fi
PAGE and Coomassie stain. A representative gel is shown of at least two indepe
(C) HeLaIL-36RSEAP cells were stimulated with IL-36b, IL-36bR5A, or IL36bF53A (50
necrosis factor kB (NF-kB) activity was measured as a fold induction of SEAP in
determined by ELISA.
(D) HeLaIL-36RSEAP cells were stimulated with IL-36b, IL-36bR5A, and IL-36bF53
neutrophil degranulate. After 24 hr, NF-kB activity was measured as a fold indu
supernatants were determined by ELISA.
(E) Recombinant IL-36g (2 mg) was incubated with elastase (50 nM). Samples we
degradation sequencing. Also shown is a schematic representing the elastase G
(F) Recombinant IL-36g and IL-36gV15G (2 mg) were incubated with a fixed con
Coomassie stain. A representative gel is shown of at least two independent exp
(G and H) HeLaIL-36RSEAP cells were either left untreated or stimulated with IL-
concentrations of elastase (G) or PMA-activated neutrophil degranulate (H). After
ELISA.
(I) Recombinant IL-36a (2 mg) was incubated with the indicated concentrations o
indicated bands were analyzed by Edman degradation sequencing. A represent
(J) Schematic representing cathespin G, elastase, and proteinase-3 cleavage mo
All data shown are representative of at least three independent experiments. ***p
Cating role in psoriasis, especially in individuals lacking endoge-
nous buffers of IL-36 activity, such as deficiency in the IL-36R
antagonist (Marrakchi et al., 2011; Farooq et al., 2013; Onoufria-
dis et al., 2011; Kanazawa et al., 2013).
An interesting question that emerges from our data is why
there is selectivity between neutrophil proteases for activation
of particular IL-36 cytokines. One reason might be to preclude
pathogen-encoded protease inhibitors from simultaneously
blocking activation of all members of this family through neutral-
izing a single protease (Eggers et al., 2004). Another reason
may be to prevent runaway escalation of inflammation through
a single protease that simultaneously activates multiple mem-
bers of the IL-1 family.
Neutrophil-Derived Proteases as Amplifiers of
Inflammation
Although neutrophils are adept at engulfing and killing microbial
agents by means of their granule enzymes, these destructive
enzymes can also be released into the extracellular space
either through degranulation or the formation of neutrophil
extracellular traps (Brinkmann et al., 2004; Amulic et al.,
2012). Although neutrophils are classically viewed as efficient
microbial killers, these cells are also recruited abundantly to
sites of sterile injury. This begs the question of why neutrophils
are needed within a tissue in the absence of infection. Although
neutrophil recruitment in these instances may serve as a safe-
guard against infection, it is also possible that these cells play
an important role in coordinating inflammatory responses by
amplifying the actions of cytokines, such as IL-36, that are
released via tissue injury. Therefore, neutrophil recruitment
may serve two major roles in immunity: pathogen elimination
and amplification of immune responses through recruitment
of other immune cells via the modulation of cytokine produc-
tion. Moreover, previous studies have suggested that neutrophil
proteases do indeed play an important immune-regulatory role
that goes beyond their role in pathogen elimination (reviewed inin IL-36 Cytokines
r at 37C (Coomassie stain). The indicated bands were analyzed by Edman
d DTEF53 cleavage motifs. A representative gel is shown of at least two inde-
xed concentration of cathepsin G, as indicated, followed by analysis by SDS-
ndent experiments.
0 pM) pre-incubated for 2 hr at 37C with a titration of cathepsin G. After 24 hr,
the supernatant, and cytokine concentrations in the culture supernatants were
A (500 pM) pre-incubated for 2 hr at 37C with a titration of PMA-activated
ction of SEAP in the supernatant, and cytokine concentrations in the culture
re resolved by Coomassie stain. The indicated band was analyzed by Edman
RAV15 cleavage motif in IL-36g.
centration of elastase, as indicated, followed by analysis by SDS-PAGE and
eriments.
36g or IL-36gV15G (500 pM) pre-incubated for 2 hr at 37C with the indicated
24 hr, cytokine concentrations in the culture supernatants were determined by
f cathepsin G and elastase. Samples were resolved by Coomassie stain. The
ative gel is shown of at least two independent experiments.
tifs within IL-36 cytokines.
< 0.0001, **p < 0.001, *p < 0.1, Student’s t test. See also Figure S4.
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Figure 6. Activated IL-36 Initiates a Global Pro-inflammatory Response from Primary Keratinocytes
(A) Heatmap of IL-36bCatG-induced genes in primary keratinocytes at 8 hr.
(B) Primary keratinocytes were stimulated with IL-36bFL or IL-36bCatG (5 nM). At the indicated time points, the levels of cytokine mRNA transcripts were quantified
by RT-PCR.
(C and D) Primary keratinocytes were stimulated for 24 hwith either IL-36bFL or IL-36bCatG (5 nM). At the indicated time points, G-CSF, GM-CSF, IL-8, CXCL1, and
CCL20 concentrations in the culture supernatants were determined by ELISA (C). Primary human keratinocytes were stimulated for 48 hr with either IL-36bFL or
IL-36bCatG (5 nM) as shown. At the indicated time points, IL-17C concentrations in the culture supernatants were determined by ELISA (D).
Error bars represent the mean ± SEM of triplicate determinations from a representative experiment. All data shown are representative of at least three inde-
pendent experiments. ***p < 0.0001, **p < 0.001, *p < 0.1, Student’s t test. See also Figure S5.Pham, 2006). The major neutrophil-derived proteases elastase,
cathepsin G, and proteinase 3 have been implicated frequently
in amplifying and sustaining inflammatory responses via pro-
cessing of extracellular proteins, although no consistent
mechanism has been identified to date (Adkison et al., 2002;
Meyer-Hoffert and Wiedow, 2011; Lefranc¸ais et al., 2012). Di-
peptidyl peptidase 1 (DPPI)-deficient mice, which are defective
in the activation of all major neutrophil serine proteases, exhibit718 Cell Reports 14, 708–722, February 2, 2016 ª2016 The Authorsdramatically reduced recruitment of neutrophils to inflammatory
sites as well as a reduced incidence of certain experimental
autoimmune diseases (Adkison et al., 2002; Pham, 2006).
Furthermore, neutrophil recruitment to sites of injury or infection
seems to be a pre-requisite for recruitment of macrophages
and monocytes. These and other observations strongly suggest
that neutrophil-derived proteases play important roles in ampli-
fying inflammation, which may be explained by their ability to
AB
C
D
Figure 7. Active IL-36b Perturbs Differentiation in an Organotypic Skin Model, and Psoriatic Skin Displays Elevated Cathepsin G Protease
Activity Sufficient to Activate IL-36b
(A) Organotypic skin reconstructs cultivated at the air-to-liquid interface were stimulated topically with either cathepsin G alone, IL-36bFL (2 nM), or IL-36bCatG
(2 nM). Skin sections were stained with H&E against filaggrin, involucrin, and cytokeratin 10 and 14, as indicated, to display epidermal thickness and differen-
tiation.
(B) Quantification of epidermal thickness using ImageJ software.
(C) Enzymatic activity in control (n = 6) or psoriatic skin (n = 6) elutes was measured using suc-FLF-sBzl and AAPV-AMC synthetic peptides to assess cathepsin
G-like and elastase-like activity, respectively.
(D) Left: HeLaIL-36R cells were stimulated with IL-36a or IL-36g (500 pM) pre-incubated for 2 hr at 37Cwith control skin (n = 6) or psoriatic skin (n = 6) elutes. After
24 hr, cytokine concentrations in the culture supernatants were determined by ELISA. Right: HeLaIL-36R cells were stimulated with IL-36b (500 pM) pre-incubated
(legend continued on next page)
Cell Reports 14, 708–722, February 2, 2016 ª2016 The Authors 719
process and activate members of the IL-36 family of cyto-
kines, as we have shown here. Therefore, targeted inhibition
of neutrophil-derived proteases may be beneficial in the treat-
ment of inflammatory skin conditions such as psoriasis.
EXPERIMENTAL PROCEDURES
Reagents
Polyclonal antibodies were generated against IL-36a, b, and g proteins by
repeated immunization of rabbits with the full-length recombinant IL-36
proteins (Biogenes). Anti-IL-1a (AHP281G) was obtained from AbD Serotec.
Anti-IL-1b (MAB201) antibody was from R&D Systems. Anti-IL-18 (ab68435)
antibody was obtained from Abcam. Anti-PCDGF (40-3400) was obtained
from Thermo Fisher Scientific. Anti-elastase (clone NP57, sc-53388) was
obtained from Santa Cruz Biotechnology. Anti-proteinase-3 (clone 6A6) was
obtained from Euro Diagnostica. Protein A/G PLUS agarose (sc-2003) was ob-
tained from Santa Cruz Biotechnology. The synthetic peptides Ac-DEVD-
AMC, Ac-WEHD-AMC, and biotin-VAD-FMK were all purchased from
Bachem. Suc(oMe)-AAPV-AMC was purchased from Peptanova. Biotin-
VAD-FMK was purchased from ICN. The novel synthetic peptides biotin-
FLF-CMK and z-FLF-CMK were synthesized by Boston Open Labs. The
chemical inhibitors cathepsin G inhibitor I (219415) and elastase inhibitor IV
(324759) were purchased from Calbiochem. Purified neutrophil-derived
cathepsin G was purchased from Calbiochem. Purified neutrophil-derived
elastase was purchased from Serva. Purified neutrophil-derived proteinase-
3 was purchased from Enzo Scientific. Unless indicated otherwise, all other
reagents were purchased from Sigma.
Cell Culture
HeLa cells were cultured in RPMI medium (Gibco) supplemented with 5% fetal
calf serum (FCS). HaCat cells were cultured in DMEM (GIBCO) supplemented
with FCS (10%). Primary neonatal foreskin-derived keratinocytes P0 were pur-
chased from Cell Systems and cultured in serum-free Dermalife K medium
(Cell Systems). KG-1 cells were cultured in RPMI medium (Gibco) supple-
mented with 10% FCS, 10% sodium pyruvate, and 10% non-essential amino
acids. The HeLa.vector and HeLa.IL-36R cell lines were generated by trans-
fection with the pCXN2.empty or pCXN2.IL-1Rrp2 (IL-36R) plasmids, followed
by selection using G-418 antibiotic (Sigma). IL-36R-overexpressing clones
were expanded from a single cell. Clones were selected by demonstration
of acquired optimal responsiveness to active forms of IL-36 via ELISA. The
HeLa.IL-36R.SEAP cell line was generated by transfection with the pNifty2-
SEAP plasmid (InvivoGen), followed by selection using zeocin antibiotic.
Clones were expanded from a single cell and tested for secreted alkaline phos-
phatase (SEAP) production. All cells were cultured at 37C in a humidified
atmosphere with 5% CO2.
Expression and Purification of Recombinant Proteins
Full-length IL-36a, b, and g proteins were generated by cloning the human cod-
ing sequences in-frame with the poly-histidine tag sequence in the bacterial
expression vector pET45b. Individual clones were sequence-validated. Protein
was expressed by addition of 600 mM isopropyl b-D-1-thiogalactopyranoside
(IPTG) to exponentially growing cultures ofE. coli (BL21 strain), followedby incu-
bation for 3 hr at 37C. Bacteria were lysed by sonication, and poly-histidine
tagged proteins were captured using nickel-nitrilotriacetic acid (NTA) agarose
(QIAGEN), followed by elution into PBS (pH 7.2) in the presence of 100mM imid-
azole. Modified forms of IL-36 that included a caspase-3-processing motif
(DEVD) were cloned into the IL-36 sequences N-terminal to the known process-
ingsites (Towneetal., 2011).All IL-36mutantswereexpressedandpurified in the
same way. Recombinant poly-histidine-tagged caspase-1 and caspase-3 were
expressed and purified as described previously (Walsh et al., 2011).for 2 hr at 37C with control skin (n = 6) or psoriatic skin (n = 6) elutes in the pres
concentrations in the culture supernatants were determined by ELISA.
Error bars represent the mean ± SEM of triplicate determinations of a representat
experiments. ***p < 0.0001, **p < 0.001, *p < 0.1, Student’s t test.
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Primary human neutrophils were purified from donor whole blood using the
Ficoll-Hypaque gradient method as described previously (Haslett et al.,
1985). The purity of the cell preparations (>90%) was determined by H&E
staining of cytospins. To prepare degranulates, neutrophils (107 per treatment)
were stimulated in the presence or absence of 50 nM PMA in Hank’s balanced
salt solution (HBSS)/0.25% BSA for 1–3 hr at 37C in a humidified atmosphere
with 5% CO2. Supernatants were harvested and clarified by centrifugation
at 4C (10,000 3 g for 5 min). Neutrophil degranulate aliquots were stored
at 80C.
Protease Activity Assays
Reactions (50 ml, final volume) were carried out in protease reaction buffer
(50 mM HEPES [pH 7.2], 75 mM NaCl, and 0.1% 3-[(-cholamidopropyl)dime-
thylammonio]-1-propanesulfonate [CHAPS] [2 mM DTT added only for cas-
pases]) containing Ac-DEVD-AFC, Ac-WEHD-AMC, and Suc(oMe)-AAPV-
AMC (50 mM, final concentration). Samples were measured by using an
automated fluorimeter (SPARK 10M, Tecan) at wavelengths of 430 nm (excita-
tion) and 535 nm (emission). For the suc-FLF-sBzl hydrolysis assay, the sub-
strate was diluted to a final concentration of 300 mM in protease reaction
buffer (50 mM HEPES [pH 7.2], 75 mM NaCl, 0.1% CHAPS, and 300 mM
5,50-dithiobis(2 nitrobenzoic acid [DTNB]). Cathepsin G hydrolyzes the syn-
thetic substrate suc-FLF-sBzl with the release of the thiobenzyl group. The
free thiobenzyl group reacts with DTNB and produces a chromophore
(3,30,5,50-tetramethylbenzidine [TNB]) that absorbs at 430 nm. Samples were
measured by automated fluorimeter (SPARK 10M).
Protease Cleavage Assays
Reactions (40–100 ml, final volume) were carried out in protease reaction buffer
(50 mM HEPES [pH 7.2], 75 mM NaCl, and 0.1% CHAPS) for 2 hr at 37C. For
IL-36 bioassays, IL-36 cytokines were typically cleaved at a 50-nM concentra-
tion and subsequently diluted onto target cells at a final concentration ranging
from 0.25–2 nM.
Tape Strip Samples from Control and Psoriatic Skin
Fixomull (2 3 2 cm) adhesive tape strips were applied to healthy or psoriatic
skin under firm pressure for 10 s. The tape strips were removed gently, placed
in sterile 1.5-ml Eppendorf tubes, and eluted with protease reaction buffer
(PRB) (50 mM HEPES [pH 7.2]/75 mM NaCl/0.1% CHAPS) under constant
rotation for 1 hr at 4C. Skin eluates were stored at 80C. Enzymatic activity
of control and psoriatic skin eluates was measured using the protease activity
assays outlined above. Bioassays were conducted according to the protease
cleavage assays outlined above.
Gene Expression Microarray Analysis
Primary human neonatal foreskin-derived keratinocytes (passage 3) were used
for gene expression analysis. Primary keratinocytes were stimulated with full-
length or cathepsin G-activated IL-36b for 8 hr. Cells were harvested with
RNAprotect cell reagent (QIAGEN) and stored at 80C. Analyses of samples
were performed by IMGM Laboratories using the SurePrint G3 Human Gene
Expression 8x60K v2 microarray using a one-color-based hybridization proto-
col. Gene expression analysis and the generation of heatmaps was conducted
using software available from http://www.chibi.ubc.ca/matrix2png/bin/
matrix2png.cgi.
SUPPLEMENTAL INFORMATION
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